A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
Latest Information Update: 04 Dec 2024
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Leiomyoma; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 17 Sep 2022 Planned number of patients changed from 42 to 65.
- 17 Sep 2022 Status changed from suspended to recruiting.
- 21 Jun 2022 Status changed from recruiting to suspended.